Background {#Sec1}
==========

Benign Lung tumors are rare, ranging from 2 to 5% of all lung tumors. Smooth muscle lesions originating in the lung represent 2% of benign lung tumors \[[@CR1]\]. Nodular smooth muscle proliferation (NSMP) has been described in detail elsewhere \[[@CR2]\]. However, no published reports included in PubMed have examine the radiological and pathological findings of NSMP. Here, we report two cases of NSMP that required differentiation from primary lung cancer.

Case presentation {#Sec2}
=================

Case report:1 {#Sec3}
-------------

An 81-year-old man had undergone a right upper lobectomy for right upper lobe lung cancer. Two years postoperatively, chest computed tomography (CT) revealed a nodular shadow with ground glass opacity (GGO) in the lower right lobe, suggesting a second primary lung cancer, although the patient was asymptomatic (Fig. [1](#Fig1){ref-type="fig"}). ^18^F-fluorodeoxyglucose - positron emission tomography (^18^FDG-PET) was not performed preoperatively because the lesion was small. The patient consented to a thoracoscopic partial resection of the right lower lobe for diagnosis and treatment. Pathological findings revealed a white-colored, 10-mm nodule with an unclear boundary just below the pleura. Hematoxylin and eosin staining revealed spindle-shaped cells with eosinophilic cytoplasm that had proliferated in a dendritic manner (Fig. [2](#Fig2){ref-type="fig"}). Immunohistochemistry revealed desmin and alpha-smooth muscle actin positivity. A diagnosis of NSMP was made. No postoperative recurrence has been observed without additional postoperative treatment. Fig. 1Chest computed tomography. a 12-mm right lower lobe nodule with ground glass opacityFig. 2Pathological findings. Dendritic growth of smooth muscle tissue seen, with an unclear boundary between normal tissue and the lesion (Hematoxylin and Eosin stain × 20)

Case report:2 {#Sec4}
-------------

A 72-year-old woman with no symptoms had a medical checkup, and a subsequent CT revealed a nodular shadow in the left lower lobe (Fig. [3](#Fig3){ref-type="fig"}). ^18^FDG-PET was not performed preoperatively because the lesion was small. We suspected a primary lung cancer, and the patient consented to a thoracoscopic partial resection of the left lower lobe for diagnosis and treatment. Pathological findings revealed a 5-mm nodule with an unclear boundary. Hematoxylin and eosin staining revealed collagen fibers, bronchiolar metaplasia, lymphocyte-induced inflammatory cell infiltration, and smooth muscle dendritic growth with foamy histocytes (Fig. [4](#Fig4){ref-type="fig"}), Immunohistochemistry revealed desmin and alpha-smooth muscle actin positivity. A diagnosis of NSMP was made. The patient received no postoperative treatment, and no recurrence has been observed. Fig. 3Chest computed tomography. a 6-mm left lower lobe nodule with ground glass opacityFig. 4Pathological findings. Dendritic growth of smooth muscle tissue (Hematoxylin and eosin stain, × 20)

Discussion/conclusion {#Sec5}
=====================

The histopathological features of NSMP resemble those of hamartoma and leiomyoma \[[@CR2]\], as all three lesions exhibit a proliferation of spindle-shaped cells and smooth muscle upon hematoxylin and eosin staining. Although an immunohistochemical analysis of NSMP reveals desmin and SMA positivity, this is not useful for differentiation from hamartoma or leiomyoma. The difference is that NSMP lesions contain more smooth muscle compared to hamartomas. NSMP also differs from leiomyoma in lesion size. Although no specific definition or standard of NSMP has been established, pathological findings indicate that NSMP exhibits dendritic smooth muscle proliferation, which results in unclear edges. This margin type clearly differs from the smooth margins of leiomyomas and hamartomas. In our cases, the smooth muscle tissue within the lesions appeared dendritic, with an undefined border. In addition, no tissue growth other than smooth muscle tissue was observed in the lesions, which was unlike a hamartoma. These pathological findings led us to diagnose NSMP in both cases. We speculated that the GGO observed around the nodules on preoperative CT was due to the spread of the smooth muscle tissue in a dendritic manner.

A previous report identified fatal pulmonary hypertension as a complication associated with diffuse smooth muscle proliferation on the lungs, which results from pulmonary artery distortion and occlusion by smooth muscle tissue and localized thrombosis \[[@CR3]\]. In both our cases, pulmonary hypertension or symptoms of the right heart failure, such as dyspnea, palpitation and edema, were not observed because smooth muscle proliferation was localized, rather than diffuse. However, additional research is needed to determine whether localized smooth muscle proliferation affects pulmonary hypertension. Both patients in this report underwent a partial resection, and neither received postoperative treatment or developed a recurrence. However, some reports of smooth muscle lesions have described malignant transformation \[[@CR4]\] and high malignancy \[[@CR5]\]. Furthermore, the postoperative follow-up period remains controversial. Further studies are required to understand the treatment and postoperative strategies in managing NSMP. In conclusion, this report demonstrates that NSMP can be distinguished from leiomyoma and hamartoma by imaging features and pathological findings. To our knowledge, this is the first report to review the radiological and pathological findings of NSMP, and it will serve to improve patient outcomes.
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:   computed tomography
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:   nodular smooth muscle proliferation
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